Developer docs
API playgroundTry for free, no card

Search company profiles

VoxCell

Full company profile

uuid0000nen

Namestring
VoxCell
Legal namestring
VoxCell BioInnovation Inc.
Websiteurl
voxcell.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

VoxCell BioInnovation Inc. is a privately held Canadian biotechnology company headquartered in Victoria, British Columbia, founded in 2020 (with company history referencing 2022 milestones). VoxCell develops and commercializes 3D bioprinted vascularized human tissue models for preclinical drug development, targeting pharmaceutical, biotechnology, CRO, and academic customers seeking human-relevant alternatives to animal models and traditional 2D cell culture. The company's core offering is an integrated platform combining a high-resolution laser-based two-photon polymerization (2PP) bioprinter (submicron resolution down to 500 nm feature size), proprietary patent-protected bioink formulations (>80% cell viability post-printing), and a proprietary Vascularization Engine software that generates customizable 3D vasculature structures using Murray's law-based branching optimization and real-time perfusion simulation. End products include ready-to-use indication-specific tissue models (TNBC, NSCLC, acellular, with neuro, skin, and ocular in development), standard-format microfluidic chips (6/24/32-well plates compatible with existing imaging setups), custom tissue development, and fee-for-service drug screening studies. Tissues are validated as viable for long-term culture up to 21 days, enabling multi-dose and combination studies; vascular wall shear stress matches human capillary range (1-10 dyn/cm²) and Paclitaxel dose-response curves in TNBC models have been shown to match clinical outcomes.

VoxCell operates a B2B-only revenue model with quote-based pricing for catalog products, custom development under statement-of-work agreements, and fee-for-service testing, all denominated in Canadian dollars with 30-day payment terms and products labeled Research Use Only. Distribution is through direct enterprise sales, partnership-driven GTM (with named partners including Altasciences, adMare BioInnovations, ValiRx, TheryCell, NMI, BC Cancer, UVic, UC San Diego, UC Santa Cruz, STEMCELL Technologies, and AbCellera), and a quote-based website storefront. A CCO was appointed in January 2026 to scale commercial execution as the FDA's April 2025 roadmap to phase out animal models in preclinical drug development and the broader Microphysiological Systems (NAMs) regulatory tailwind accelerate customer adoption. VoxCell is co-founder-led by CEO/CSO Dr. Karolina Valente, with advisory support from Stanford's Dr. Mark Pegram; the board includes Altasciences President Marie-Helene Raigneau and executives from E-Fund, RocketBio, and Constellation Software.

The company has raised cumulative disclosed equity funding of approximately $3.4M across 2020-2025 (including rounds led by E-Fund with Archangel Network of Funds, Women's Equity Lab, Phoenix Fire, and WUTIF, plus impact investor capital from Spring Activator/TELUS Pollinator Fund), augmented by non-dilutive grants including the VIATEC BOOST program (backed by a $2.5M Government of Canada investment) and Province of BC / Innovate BC funding announced April 2026. The company has won multiple recognitions including the 2025 Globe & Mail Changemakers Award and the 2022 Spring Activator Women-led Impact Investor Challenge.

Short descriptiontext

VoxCell BioInnovation is a Canadian biotech that builds 3D bioprinted vascularized human tissue models for preclinical drug development, serving pharmaceutical, biotechnology, CRO, and academic customers with an integrated two-photon polymerization platform, proprietary bioinks, and Vascularization Engine software.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVictoria, Canada
HQ citystring
Victoria
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D bioprinting, tissue engineering, preclinical drug development, vascularized tissue models, microphysiological systems
Industry2 codes
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
3D Bioprinted Tissue Models
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Catalog Product Sales
TypeHardware Sales
Description

Sale of ready-to-use Products including reagents, consumables, microfluidic chips, and standard tissue models at then-current published catalog prices; FCA shipping point (Incoterms 2020); 30-day payment terms; Canadian dollar denominated.

voxcell.com
2Custom Product Development
TypeProfessional Services
Description

Custom Products developed per customer's written instructions/specifications/statement of work; quote-based pricing; mutually agreed specifications.

voxcell.com
3Fee-for-Service Testing
TypeProfessional Services
Description

Print-and-ship services and fee-for-service testing available; customers can contract VoxCell to run drug screening, safety/efficacy, or tissue characterization studies using its vascularized tissue platform.

voxcell.com
4Strategic Partnerships
TypeManaged Services
Description

Multi-year research partnerships with pharmaceutical/biotech companies (e.g., adMare, Altasciences, ValiRx, Inaphea, TheryCell, NMI) for collaborative validation, immuno-oncology biologic evaluation, and translational research; partnership model initiated 2024-2026.

voxcell.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details3 tiers
1Catalog Products — standard ready-to-use tissue models, reagents, consumables at published catalog prices.
ModelOtherBilling cadenceOther
Notes

Quote-based via Customer Experience Department (1-672-974-8850) or www.voxcellbio.com; priced at then-current published catalog prices, changeable without notice; billed in Canadian dollars.

voxcell.com
2Custom Products — modified per customer's specifications under a separate written agreement/statement of work.
ModelOtherBilling cadenceOther
Notes

Quoted based on mutually agreed specifications; governed by separate written agreement.

voxcell.com
3Fee-for-Service Testing — contract research using VoxCell's platform.
ModelOtherBilling cadenceOther
Notes

Quote-based; available via contact form / Customer Experience Department.

voxcell.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

VoxCell manufactures and sells 3D bioprinted, perfusable vascularized human tissue models (including TNBC, NSCLC, acellular, neuro, skin, and ocular variants) produced via its proprietary two-photon polymerization bioprinting platform, patent-protected bioinks, and Vascularization Engine software. The company also offers custom product development, fee-for-service drug screening and tissue characterization studies, and multi-year research partnerships for preclinical drug development customers in pharma, biotech, CRO, and academic sectors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 90% of drugs fail in human studies despite passing animal studies — VoxCell's platform is positioned to address this translational gap.
+5 more records
Product overview1 text field

VoxCell BioInnovation offers a single integrated 3D bioprinting platform rather than a separately modular product suite. The High-Resolution Laser Bioprinting Platform is the underlying technology foundation; it is combined with the Proprietary Bioink Cartridge System and the Vascularization Engine Software to produce the company's core offering, 3D Vascularized Human Tissue Models. These ready-to-use, perfusable tissue models are sold as indication-specific variants including the TNBC Tissue Model, NSCLC Tissue Model, and Acellular Tissue Model, with additional development in Cancer, Neuro, Skin, and Ocular indications. VoxCell also offers custom development, fee-for-service testing, and fee-based tissue printing shipped directly to customers.

Product and service6 records
13D Vascularized Human Tissue Models
Category3D bioprinted tissue models
Description

Bioprinted, perfusable 3D human tissue models with functional endothelial-lined vascular networks used for preclinical drug efficacy, safety, ADME, and combination studies. Delivered ready-to-use in microfluidic chips across multiple indication formats including TNBC, NSCLC, Acellular, Cancer, Neuro, Skin, and Ocular; sold to pharmaceutical, biotechnology, CRO, and academic customers.

2TNBC (Triple-Negative Breast Cancer) Tissue Model
Category3D bioprinted tissue models
Description

A vascularized 3D bioprinted tumor model validated with Paclitaxel that demonstrates dose-dependent responses matching clinical outcomes and supports assessment of drug penetration, distribution, and vascular toxicity in triple-negative breast cancer research.

3NSCLC (Non-Small Cell Lung Cancer) Tissue Model
Category3D bioprinted tissue models
Description

A vascularized 3D bioprinted tumor model produced with NCI-H460 cells and patient-derived materials, demonstrating tumor formation and T cell extravasation for immunotherapy screening in non-small cell lung cancer research.

4Acellular Tissue Model
Category3D bioprinted tissue models
Description

An acellular vascularized tissue construct used as a baseline/control model alongside cellular TNBC and NSCLC models for drug screening studies.

5Custom Product Development
CategoryCustom tissue model development services
Description

Custom tissue models and bioprinted products developed per customer's written instructions, specifications, and statement of work, with quote-based pricing under a separate written agreement. Available to pharmaceutical, biotechnology, CRO, and academic customers requiring indication- or application-specific tissue models.

6Fee-for-Service Drug Screening and Tissue Testing
CategoryContract research services
Description

Contract research services in which VoxCell runs drug screening, safety/efficacy, or tissue characterization studies on behalf of customers using its vascularized tissue platform, available via print-and-ship services and the Customer Experience Department.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Research partnership announced May 13, 2026 to validate the scientific and commercial potential of a novel antibody-based immune-modulating therapy using VoxCell's human-relevant vascularized cancer tissue models. The collaboration will apply perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics. Data generated will inform adMare's program development and contribute to qualifying VoxCell's vascularized cancer tissue model as a reference NAM for immuno-oncology biologics. Commenced 2026.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-07-31
Description

Strategic collaboration announced July 31, 2025 to enhance preclinical research and accelerate drug development timelines by combining Altasciences' early-phase drug development capabilities with VoxCell's 3D bioprinting and human-like tissue modeling technology. The partnership will initially focus on drug screening for ocular indications before expanding to other therapeutic areas. Altasciences President Marie-Helene Raigneau sits on VoxCell's Board of Directors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Collaboration (Canada) in partnership with University of Victoria, focused on radiation oncology. Evaluating nanoparticle-enhanced radiation therapy and treatment outcomes using VoxCell's vascularized breast cancer tissue models. Commenced 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Collaboration (Canada) with BC Cancer on radiation therapy research commenced 2025; ongoing academic collaboration including joint publications on GelMA microspheres (Pharmaceutics 2024) and oncology screening review (Cancers 2023).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Collaboration (Germany, commenced 2024) with NMI on T cell tissue modeling and immunotherapy screening applications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Collaboration (Germany) with TheryCell on T cell tissue modeling and immunotherapy screening, commenced 2024.

7ValiRx
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration (United Kingdom) with Inaphea BioLabs on breast cancer tissue models; evolving models and testing novel therapeutics using patient-derived cells for T cell screening and immunotherapy applications.

voxcell.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration (United Kingdom) with ValiRx on breast cancer tissue model validation and novel therapeutic screening using patient-derived cells for T cell screening and immunotherapy.

9University of California San Diego
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration (United States) on neuro indication studies; partnering with Open Culture Science on neuro tissue modeling.

voxcell.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration (United States) with University of California San Diego on neuro indication tissue modeling.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaborating academic institution on VoxCell's partnerships page alongside UC San Diego.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Listed as a partner on VoxCell's partnerships page; STEMCELL Technologies is a Canada-based life sciences tools company. CCO Graham Craig previously worked at STEMCELL Technologies leading corporate initiatives.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on VoxCell's partnerships page (Canada). CCO Graham Craig joined VoxCell from AbCellera, where he was Director of Corporate Development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct peer in 3D bioprinted human tissues for preclinical drug discovery and disease modeling. Competes head-to-head with VoxCell in vascularized tissue models for pharma/biotech customers.

2Aspect Biosystems
TypeDirect peer
Description

Direct peer in microfluidic 3D bioprinting of physiologically relevant human tissues for drug development and tissue therapeutics. Targets the same pharma/biotech preclinical testing market with vascularized tissue constructs.

TypeDirect peer
Description

Direct peer providing bioprinters, bioinks, and lab automation for 3D cell culture and tissue engineering. Sells complementary bioprinting platform technology and consumables to the same research customer base.

TypeDirect peer
Description

Direct peer in organ-on-chip and microphysiological systems (MPS) for preclinical drug testing. Competes in the same vascularized, human-relevant in vitro model category for pharma R&D.

TypeDirect peer
Description

Direct peer in organ-on-chip technology and 3D tissue models for drug discovery and safety assessment. Competes in the same NAM/MPS preclinical testing category.

6CN Bio
TypeDirect peer
Description

Direct peer in microphysiological systems and organ-on-chip platforms for drug development. Targets pharma customers evaluating NAMs as alternatives to animal models.

TypeDirect peer
Description

Direct peer in 3D microtissue and organoid platforms for drug safety, efficacy, and disease modeling in preclinical research. Overlaps with VoxCell's pharma/biotech customer base.

TypeDirect peer
Description

Direct peer in 3D bioprinting systems and bioinks for regenerative medicine and tissue engineering research. Sells bioprinters and consumables to similar academic/biotech research labs.

TypeBroad incumbent
Description

Broad incumbent with a bioprinting and regenerative medicine effort (formerly via Allevi) selling bioprinters and biomaterials. Larger and more diversified, with bioprinting as one product line among many industrial 3D printing offerings.

TypeDirect peer
Description

Direct peer in 3D bioprinting of vascularized cellular constructs using its Regenova platform. Targets regenerative medicine and drug discovery with similar perfusable tissue technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VoxCell

3D Bioprinted Tissue Modelsvoxcell.com

VoxCell BioInnovation is a Canadian biotech that builds 3D bioprinted vascularized human tissue models for preclinical drug development, serving pharmaceutical, biotechnology, CRO, and academic customers with an integrated two-photon polymerization platform, proprietary bioinks, and Vascularization Engine software.

What VoxCell does

VoxCell BioInnovation Inc. is a privately held Canadian biotechnology company headquartered in Victoria, British Columbia, founded in 2020 (with company history referencing 2022 milestones). VoxCell develops and commercializes 3D bioprinted vascularized human tissue models for preclinical drug development, targeting pharmaceutical, biotechnology, CRO, and academic customers seeking human-relevant alternatives to animal models and traditional 2D cell culture. The company's core offering is an integrated platform combining a high-resolution laser-based two-photon polymerization (2PP) bioprinter (submicron resolution down to 500 nm feature size), proprietary patent-protected bioink formulations (>80% cell viability post-printing), and a proprietary Vascularization Engine software that generates customizable 3D vasculature structures using Murray's law-based branching optimization and real-time perfusion simulation. End products include ready-to-use indication-specific tissue models (TNBC, NSCLC, acellular, with neuro, skin, and ocular in development), standard-format microfluidic chips (6/24/32-well plates compatible with existing imaging setups), custom tissue development, and fee-for-service drug screening studies. Tissues are validated as viable for long-term culture up to 21 days, enabling multi-dose and combination studies; vascular wall shear stress matches human capillary range (1-10 dyn/cm²) and Paclitaxel dose-response curves in TNBC models have been shown to match clinical outcomes.

VoxCell operates a B2B-only revenue model with quote-based pricing for catalog products, custom development under statement-of-work agreements, and fee-for-service testing, all denominated in Canadian dollars with 30-day payment terms and products labeled Research Use Only. Distribution is through direct enterprise sales, partnership-driven GTM (with named partners including Altasciences, adMare BioInnovations, ValiRx, TheryCell, NMI, BC Cancer, UVic, UC San Diego, UC Santa Cruz, STEMCELL Technologies, and AbCellera), and a quote-based website storefront. A CCO was appointed in January 2026 to scale commercial execution as the FDA's April 2025 roadmap to phase out animal models in preclinical drug development and the broader Microphysiological Systems (NAMs) regulatory tailwind accelerate customer adoption. VoxCell is co-founder-led by CEO/CSO Dr. Karolina Valente, with advisory support from Stanford's Dr. Mark Pegram; the board includes Altasciences President Marie-Helene Raigneau and executives from E-Fund, RocketBio, and Constellation Software.

The company has raised cumulative disclosed equity funding of approximately $3.4M across 2020-2025 (including rounds led by E-Fund with Archangel Network of Funds, Women's Equity Lab, Phoenix Fire, and WUTIF, plus impact investor capital from Spring Activator/TELUS Pollinator Fund), augmented by non-dilutive grants including the VIATEC BOOST program (backed by a $2.5M Government of Canada investment) and Province of BC / Innovate BC funding announced April 2026. The company has won multiple recognitions including the 2025 Globe & Mail Changemakers Award and the 2022 Spring Activator Women-led Impact Investor Challenge.

VoxCell firmographics

Firmographics
Name
VoxCell
Legal name
VoxCell BioInnovation Inc.
Website
https://voxcell.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
VoxCell BioInnovation is a Canadian biotech that builds 3D bioprinted vascularized human tissue models for preclinical drug development, serving pharmaceutical, biotechnology, CRO, and academic customers with an integrated two-photon polymerization platform, proprietary bioinks, and Vascularization Engine software.
Ownership category
akta.pro rank

VoxCell industry classification

Industry
Product category
3D Bioprinted Tissue Models
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • 3D bioprinting
  • Tissue engineering
  • Preclinical drug development
  • Vascularized tissue models
  • Microphysiological systems

Where VoxCell is headquartered

Location

Headquarters

HQ city
Victoria
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

VoxCell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Catalog Product Sales: Sale of ready-to-use Products including reagents, consumables, microfluidic chips, and standard tissue models at then-current published catalog prices; FCA shipping point (Incoterms 2020); 30-day payment terms; Canadian dollar denominated.
  2. Custom Product Development: Custom Products developed per customer's written instructions/specifications/statement of work; quote-based pricing; mutually agreed specifications.
  3. Fee-for-Service Testing: Print-and-ship services and fee-for-service testing available; customers can contract VoxCell to run drug screening, safety/efficacy, or tissue characterization studies using its vascularized tissue platform.
  4. Strategic Partnerships: Multi-year research partnerships with pharmaceutical/biotech companies (e.g., adMare, Altasciences, ValiRx, Inaphea, TheryCell, NMI) for collaborative validation, immuno-oncology biologic evaluation, and translational research; partnership model initiated 2024-2026.

Pricing tiers

ModelBillingPrice
OtherOtherCatalog Products — standard ready-to-use tissue models, reagents, consumables at published catalog prices.
OtherOtherCustom Products — modified per customer's specifications under a separate written agreement/statement of work.
OtherOtherFee-for-Service Testing — contract research using VoxCell's platform.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

VoxCell product offering

Product offering

Core offering

VoxCell manufactures and sells 3D bioprinted, perfusable vascularized human tissue models (including TNBC, NSCLC, acellular, neuro, skin, and ocular variants) produced via its proprietary two-photon polymerization bioprinting platform, patent-protected bioinks, and Vascularization Engine software. The company also offers custom product development, fee-for-service drug screening and tissue characterization studies, and multi-year research partnerships for preclinical drug development customers in pharma, biotech, CRO, and academic sectors.

Product overview

VoxCell BioInnovation offers a single integrated 3D bioprinting platform rather than a separately modular product suite. The High-Resolution Laser Bioprinting Platform is the underlying technology foundation; it is combined with the Proprietary Bioink Cartridge System and the Vascularization Engine Software to produce the company's core offering, 3D Vascularized Human Tissue Models. These ready-to-use, perfusable tissue models are sold as indication-specific variants including the TNBC Tissue Model, NSCLC Tissue Model, and Acellular Tissue Model, with additional development in Cancer, Neuro, Skin, and Ocular indications. VoxCell also offers custom development, fee-for-service testing, and fee-based tissue printing shipped directly to customers.

Differentiator

Problem solved

Functional benefit

Products and services

  • 3D Vascularized Human Tissue Models Bioprinted, perfusable 3D human tissue models with functional endothelial-lined vascular networks used for preclinical drug efficacy, safety, ADME, and combination studies. Delivered ready-to-use in microfluidic chips across multiple indication formats including TNBC, NSCLC, Acellular, Cancer, Neuro, Skin, and Ocular; sold to pharmaceutical, biotechnology, CRO, and academic customers.
  • TNBC (Triple-Negative Breast Cancer) Tissue Model A vascularized 3D bioprinted tumor model validated with Paclitaxel that demonstrates dose-dependent responses matching clinical outcomes and supports assessment of drug penetration, distribution, and vascular toxicity in triple-negative breast cancer research.
  • NSCLC (Non-Small Cell Lung Cancer) Tissue Model A vascularized 3D bioprinted tumor model produced with NCI-H460 cells and patient-derived materials, demonstrating tumor formation and T cell extravasation for immunotherapy screening in non-small cell lung cancer research.
  • Acellular Tissue Model An acellular vascularized tissue construct used as a baseline/control model alongside cellular TNBC and NSCLC models for drug screening studies.
  • Custom Product Development Custom tissue models and bioprinted products developed per customer's written instructions, specifications, and statement of work, with quote-based pricing under a separate written agreement. Available to pharmaceutical, biotechnology, CRO, and academic customers requiring indication- or application-specific tissue models.
  • Fee-for-Service Drug Screening and Tissue Testing Contract research services in which VoxCell runs drug screening, safety/efficacy, or tissue characterization studies on behalf of customers using its vascularized tissue platform, available via print-and-ship services and the Customer Experience Department.

Quantifiable outcome

  • Over 90% of drugs fail in human studies despite passing animal studies — VoxCell's platform is positioned to address this translational gap.
  • +5 more outcomes

Companies that use VoxCell

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

VoxCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

VoxCell partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered flagship, core and minor.

  • adMare BioInnovationsflagshipStrategic or Co-development Partner · 13 May 2026Research partnership announced May 13, 2026 to validate the scientific and commercial potential of a novel antibody-based immune-modulating therapy using VoxCell's human-relevant vascularized cancer tissue models. The collaboration will apply perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics. Data generated will inform adMare's program development and contribute to qualifying VoxCell's vascularized cancer tissue model as a reference NAM for immuno-oncology biologics. Commenced 2026.
  • AltasciencesflagshipStrategic or Co-development Partner · 31 July 2025Strategic collaboration announced July 31, 2025 to enhance preclinical research and accelerate drug development timelines by combining Altasciences' early-phase drug development capabilities with VoxCell's 3D bioprinting and human-like tissue modeling technology. The partnership will initially focus on drug screening for ocular indications before expanding to other therapeutic areas. Altasciences President Marie-Helene Raigneau sits on VoxCell's Board of Directors.
  • BC CancercoreStrategic or Co-development Partner · 1 January 2025Collaboration (Canada) in partnership with University of Victoria, focused on radiation oncology. Evaluating nanoparticle-enhanced radiation therapy and treatment outcomes using VoxCell's vascularized breast cancer tissue models. Commenced 2025.
  • University of VictoriacoreStrategic or Co-development Partner · 1 January 2025Collaboration (Canada) with BC Cancer on radiation therapy research commenced 2025; ongoing academic collaboration including joint publications on GelMA microspheres (Pharmaceutics 2024) and oncology screening review (Cancers 2023).
  • TheryCellcoreStrategic or Co-development Partner · 1 January 2024Collaboration (Germany, commenced 2024) with NMI on T cell tissue modeling and immunotherapy screening applications.
  • NMI (Natural and Medical Sciences Institute)coreStrategic or Co-development Partner · 1 January 2024Collaboration (Germany) with TheryCell on T cell tissue modeling and immunotherapy screening, commenced 2024.
  • ValiRxcoreStrategic or Co-development PartnerCollaboration (United Kingdom) with Inaphea BioLabs on breast cancer tissue models; evolving models and testing novel therapeutics using patient-derived cells for T cell screening and immunotherapy applications.
  • Inaphea BioLabscoreStrategic or Co-development PartnerCollaboration (United Kingdom) with ValiRx on breast cancer tissue model validation and novel therapeutic screening using patient-derived cells for T cell screening and immunotherapy.
  • University of California San DiegocoreStrategic or Co-development PartnerCollaboration (United States) on neuro indication studies; partnering with Open Culture Science on neuro tissue modeling.
  • Open Culture ScienceminorStrategic or Co-development PartnerCollaboration (United States) with University of California San Diego on neuro indication tissue modeling.
  • University of California Santa CruzminorStrategic or Co-development PartnerListed as a collaborating academic institution on VoxCell's partnerships page alongside UC San Diego.
  • STEMCELL TechnologiesminorGTM or Marketing PartnerListed as a partner on VoxCell's partnerships page; STEMCELL Technologies is a Canada-based life sciences tools company. CCO Graham Craig previously worked at STEMCELL Technologies leading corporate initiatives.
  • AbCelleraminorStrategic or Co-development PartnerListed as a partner on VoxCell's partnerships page (Canada). CCO Graham Craig joined VoxCell from AbCellera, where he was Director of Corporate Development.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

VoxCell competitors and assessment

Company assessment

Direct peers

  • Organovo: Direct peer in 3D bioprinted human tissues for preclinical drug discovery and disease modeling. Competes head-to-head with VoxCell in vascularized tissue models for pharma/biotech customers.
  • Aspect Biosystems: Direct peer in microfluidic 3D bioprinting of physiologically relevant human tissues for drug development and tissue therapeutics. Targets the same pharma/biotech preclinical testing market with vascularized tissue constructs.
  • CELLINK (BICO Group): Direct peer providing bioprinters, bioinks, and lab automation for 3D cell culture and tissue engineering. Sells complementary bioprinting platform technology and consumables to the same research customer base.
  • Emulate Inc. Direct peer in organ-on-chip and microphysiological systems (MPS) for preclinical drug testing. Competes in the same vascularized, human-relevant in vitro model category for pharma R&D.
  • Mimetas: Direct peer in organ-on-chip technology and 3D tissue models for drug discovery and safety assessment. Competes in the same NAM/MPS preclinical testing category.
  • CN Bio: Direct peer in microphysiological systems and organ-on-chip platforms for drug development. Targets pharma customers evaluating NAMs as alternatives to animal models.
  • InSphero: Direct peer in 3D microtissue and organoid platforms for drug safety, efficacy, and disease modeling in preclinical research. Overlaps with VoxCell's pharma/biotech customer base.
  • Regemat 3D: Direct peer in 3D bioprinting systems and bioinks for regenerative medicine and tissue engineering research. Sells bioprinters and consumables to similar academic/biotech research labs.
  • Cyfuse Biomedical: Direct peer in 3D bioprinting of vascularized cellular constructs using its Regenova platform. Targets regenerative medicine and drug discovery with similar perfusable tissue technology.

Broad incumbents

  • 3D Systems: Broad incumbent with a bioprinting and regenerative medicine effort (formerly via Allevi) selling bioprinters and biomaterials. Larger and more diversified, with bioprinting as one product line among many industrial 3D printing offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VoxCell social profiles

Digital presence

VoxCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VoxCell leadership team

Management profile

Number of profiles

Profiles4 records

VoxCell funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VoxCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VoxCell

What does VoxCell do?

VoxCell manufactures and sells 3D bioprinted, perfusable vascularized human tissue models (including TNBC, NSCLC, acellular, neuro, skin, and ocular variants) produced via its proprietary two-photon polymerization bioprinting platform, patent-protected bioinks, and Vascularization Engine software. The company also offers custom product development, fee-for-service drug screening and tissue characterization studies, and multi-year research partnerships for preclinical drug development customers in pharma, biotech, CRO, and academic sectors.

Is VoxCell a public or private company?

VoxCell is a private company. It is classified as venture growth investor backed and is currently operating.

When was VoxCell founded?

VoxCell was founded in 2022. It employs 11 to 50 people.

Where is VoxCell based?

VoxCell is headquartered in Victoria, Canada, in the North America region.

How does VoxCell make money?

Four revenue lines are on record. Catalog Product Sales are the primary driver. The others are custom Product Development, fee-for-Service Testing and strategic Partnerships.

Who are VoxCell's main competitors?

Direct peers on record are Organovo, Aspect Biosystems, CELLINK (BICO Group), Emulate Inc., Mimetas, CN Bio, InSphero, Regemat 3D and Cyfuse Biomedical. 3D Systems is listed as a broad incumbent.

Does VoxCell have an API?

No public API is recorded for VoxCell.

What industry is VoxCell in?

VoxCell's product category is 3D Bioprinted Tissue Models. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireVoxCell BioInnovation Advances the Future of Drug Development on Inside Business Today with Hosts Bill & Giuliana RancicVoxCell BioInnovation will be featured on Inside Business Today on June 19, 2026, discussing its 3D bioprinting technology for human tissue models. The company, founded in 2020, has raised over $10 million and aims to reduce late-stage drug failures, which affect over 90% of animal-tested drugs.TechcouverVoxCell and adMare Partner to Advance More Human-Relevant Biologic TherapyVoxCell and adMare are partnering to validate a novel antibody-based immune-modulating therapy using VoxCell's vascularized tissue platform. The collaboration aims to generate stronger preclinical safety and efficacy evidence, aligning with FDA efforts to reduce animal testing. VoxCell's platform integrates human tumor, immune, and stromal compartments with perfused vasculature.EIN PresswireVoxCell BioInnovation Advances Future of Drug Development on Inside Business Today with Hosts Bill and Giuliana RancicVoxCell BioInnovation will be featured on Inside Business Today on May 15, 2026, discussing its 3D bioprinted human tissue models for drug development. The company, founded in 2020, has raised over $10 million and aims to reduce late-stage drug failures, which currently exceed 90%.Precedence Research3D Bioprinted Human Tissue Market Industry OutlookThe global 3D bioprinted human tissue market is projected to grow from USD 2.60 billion in 2025 to USD 5.67 billion by 2035, representing a compound annual growth rate of 8.13%, driven by organ donor shortages, demand for drug testing models, and advances in regenerative medicine. Market segmentation data shows skin tissue and extrusion-based bioprinting as the largest segments, with North America currently leading while Asia-Pacific registers the fastest growth. In July 2025, Altasciences and VoxCell BioInnovation announced a strategic collaboration to leverage 3D tissue technology for enhanced preclinical research.YahooAltasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug DevelopmentAltasciences and VoxCell BioInnovation announced a strategic collaboration to enhance preclinical research and accelerate drug development timelines by combining Altasciences' early-phase drug development capabilities with VoxCell's 3D bioprinting and human-like tissue modeling technology. The partnership will initially focus on drug screening for ocular indications before expanding to other therapeutic areas. Both companies aim to reduce translational gaps and offer more predictive preclinical testing environments to pharmaceutical and biotechnology clients.TechcouverVIATEC Awards to Shine Disco-Coloured Spotlight on Victoria Tech Scene in MayThe VIATEC Awards will be announced at a Spring Social event in Victoria this month, with winners revealed on May 1st. Finalists include VoxCell BioInnovation, MarineLabs, and others across categories. The event, themed DiscoTech, will feature live music and networking.PR NewswireThe Future of Medicine, Now: All Access with Andy Garcia Features VoxCell BioInnovation Inc.All Access with Andy Garcia, an educational program broadcast on Public Television stations, featured VoxCell BioInnovation Inc. to explore the company's 3D bioprinting technology that creates human-like tissue models for drug testing. The segment highlighted how these tissue models improve drug testing accuracy and offer an ethical alternative to animal testing, with potential to accelerate development of personalized medicine treatments.GreyBTop 5 3D Bioprinting Startups to Watch in 2025This article profiles five early-stage 3D bioprinting startups with growth potential in 2025: 4D Biomaterials (UK, $2.1M funding), Next Big Innovation Labs (India, developing 3D bioprinted human skin), SPEBIO (South Korea, cell aggregation platform), Brinter (USA, $2.2M funding, bioprinted implants), and VoxCell BioInnovation (Canada, $1.7M funding, vascularized cancer tissue models). The startups collectively aim to address challenges in drug development, organ transplantation, and personalized medicine through innovations in 3D bioprinting technology.Impetus DigitalRevolutionizing 3D Bioprinting & Disrupting the Drug Development IndustryChristine Whiteside, COO of VoxCell BioInnovation, discussed 3D bioprinting in a podcast, noting that over 25,000 people die from cancer daily and drug development takes over 15 years and $2 billion. She said 95% of drugs fail, and VoxCell's technology aims to reduce failure rates by testing on biomimetic tissues.MaRS Discovery DistrictInnovation update: These 7 health tech companies just joined the MaRS communitySeven Canadian healthcare startups—VoxCell BioInnovation, Malaika Vx, Health21, SanteSuite, WearAbility, KeyIntel Medical, and Oncoustics—joined MaRS, which has 27 healthcare startups in its portfolio. The companies aim to improve diagnostics, vaccines, telemedicine, and patient monitoring. MaRS expects these innovations to accelerate drug discovery and pandemic response.